Shares of NanoString Technologies, Inc. (NASDAQ:NSTG) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $20.00.

Several analysts have recently weighed in on NSTG shares. ValuEngine upgraded NanoString Technologies from a “sell” rating to a “hold” rating in a report on Saturday, July 1st. Zacks Investment Research upgraded NanoString Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Cowen and Company restated a “buy” rating and set a $20.00 price target on shares of NanoString Technologies in a report on Thursday, September 28th. BidaskClub cut NanoString Technologies from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Finally, Janney Montgomery Scott cut NanoString Technologies from a “buy” rating to a “neutral” rating in a report on Thursday.

Shares of NanoString Technologies (NSTG) traded down 33.21% on Thursday, hitting $10.46. 1,415,872 shares of the stock traded hands. The stock has a 50 day moving average of $15.72 and a 200-day moving average of $16.63. NanoString Technologies has a 1-year low of $9.56 and a 1-year high of $23.45. The stock’s market cap is $263.63 million.

NanoString Technologies (NASDAQ:NSTG) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.17. The company had revenue of $34.59 million for the quarter, compared to analysts’ expectations of $29.87 million. NanoString Technologies had a negative return on equity of 329.59% and a negative net margin of 44.28%. On average, equities research analysts expect that NanoString Technologies will post ($2.14) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/12/nanostring-technologies-inc-nstg-receives-consensus-rating-of-hold-from-analysts.html.

A number of hedge funds have recently made changes to their positions in NSTG. Teachers Advisors LLC boosted its holdings in NanoString Technologies by 7.1% in the fourth quarter. Teachers Advisors LLC now owns 23,597 shares of the biotechnology company’s stock valued at $526,000 after acquiring an additional 1,557 shares during the last quarter. American International Group Inc. boosted its holdings in NanoString Technologies by 7.4% in the first quarter. American International Group Inc. now owns 9,153 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 634 shares during the last quarter. Wellington Management Group LLP boosted its holdings in NanoString Technologies by 6.8% in the first quarter. Wellington Management Group LLP now owns 509,051 shares of the biotechnology company’s stock valued at $10,115,000 after acquiring an additional 32,541 shares during the last quarter. Vanguard Group Inc. boosted its holdings in NanoString Technologies by 2.7% in the first quarter. Vanguard Group Inc. now owns 588,558 shares of the biotechnology company’s stock valued at $11,695,000 after acquiring an additional 15,343 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in NanoString Technologies by 15.2% in the first quarter. Morgan Stanley now owns 1,886,772 shares of the biotechnology company’s stock valued at $37,490,000 after acquiring an additional 248,581 shares during the last quarter. Institutional investors and hedge funds own 92.98% of the company’s stock.

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.